Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. / Arendt Nielsen, Thomas; Sega, Rok; Uggerhøj Andersen, Carl et al.

I: Journal of Ocular Pharmacology and Therapeutics, Bind 38, Nr. 1, 01.2022, s. 114-121.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Arendt Nielsen, T, Sega, R, Uggerhøj Andersen, C, Vorum, H, Drewes, AM, Jakobsen, PE, Brock, B & Brock, C 2022, 'Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy', Journal of Ocular Pharmacology and Therapeutics, bind 38, nr. 1, s. 114-121. https://doi.org/10.1089/jop.2021.0055

APA

Arendt Nielsen, T., Sega, R., Uggerhøj Andersen, C., Vorum, H., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2022). Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. Journal of Ocular Pharmacology and Therapeutics, 38(1), 114-121. https://doi.org/10.1089/jop.2021.0055

CBE

Arendt Nielsen T, Sega R, Uggerhøj Andersen C, Vorum H, Drewes AM, Jakobsen PE, Brock B, Brock C. 2022. Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. Journal of Ocular Pharmacology and Therapeutics. 38(1):114-121. https://doi.org/10.1089/jop.2021.0055

MLA

Vancouver

Arendt Nielsen T, Sega R, Uggerhøj Andersen C, Vorum H, Drewes AM, Jakobsen PE et al. Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. Journal of Ocular Pharmacology and Therapeutics. 2022 jan.;38(1):114-121. https://doi.org/10.1089/jop.2021.0055

Author

Arendt Nielsen, Thomas ; Sega, Rok ; Uggerhøj Andersen, Carl et al. / Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy. I: Journal of Ocular Pharmacology and Therapeutics. 2022 ; Bind 38, Nr. 1. s. 114-121.

Bibtex

@article{b8583cc2243641bb98f5140ec1616ab4,
title = "Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy",
abstract = "Purpose: Liraglutide treatment has shown promising anti-inflammatory and nerve regenerative results in preclinical and clinical trials. We sought to assess if liraglutide treatment would induce nerve regeneration through its anti-inflammatory and neurotrophic mechanisms by increasing peripapillary retinal nerve fiber layer (RNFL) thickness in individuals with long-term type 1 diabetes. Methods: Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment. The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography. Results: Thirty-seven participants were included in the secondary analysis. No differences in mean peripapillary RNFL thickness (overall ΔMean RNFL thickness; liraglutide -1 (±8) μm (-1%) vs. placebo -1 (±5) μm (-1%), P = 0.78, n = 37) or any of the quadrants. Peripapillary RNFL thicknesses were shown between treatments in either nonproliferative (ΔMean RNFL thickness; liraglutide -1 (±5) μm (-1%) vs. placebo 0 (±4) μm (0%), P = 0.80, N = 26) or proliferative diabetic retinopathy subgroup (ΔMean RNFL thickness; liraglutide -2 (±14) μm (-3%) vs. placebo -1 (±6) μm (-2%), P = 0.88, N = 11). Conclusions: In this study, 26 weeks of liraglutide treatment did not induce measurable changes in the assessed optic nerve thickness. Thus, this methodology does not support the induction of substantial nerve regeneration in this cohort with established retinopathy and DSPN. The trial was approved by the Danish Health and Medicines Authority. Informed consent was obtained from all participants. ",
keywords = "diabetic retinopathy, GLP-1 agonist, liraglutide, nerve fiber layer, optical coherence tomography",
author = "{Arendt Nielsen}, Thomas and Rok Sega and {Uggerh{\o}j Andersen}, Carl and Henrik Vorum and Drewes, {Asbj{\o}rn Mohr} and Jakobsen, {Poul Erik} and Birgitte Brock and Christina Brock",
note = "Publisher Copyright: {\textcopyright} 2022 Mary Ann Liebert Inc.",
year = "2022",
month = jan,
doi = "10.1089/jop.2021.0055",
language = "English",
volume = "38",
pages = "114--121",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert",
number = "1",

}

RIS

TY - JOUR

T1 - Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy

AU - Arendt Nielsen, Thomas

AU - Sega, Rok

AU - Uggerhøj Andersen, Carl

AU - Vorum, Henrik

AU - Drewes, Asbjørn Mohr

AU - Jakobsen, Poul Erik

AU - Brock, Birgitte

AU - Brock, Christina

N1 - Publisher Copyright: © 2022 Mary Ann Liebert Inc.

PY - 2022/1

Y1 - 2022/1

N2 - Purpose: Liraglutide treatment has shown promising anti-inflammatory and nerve regenerative results in preclinical and clinical trials. We sought to assess if liraglutide treatment would induce nerve regeneration through its anti-inflammatory and neurotrophic mechanisms by increasing peripapillary retinal nerve fiber layer (RNFL) thickness in individuals with long-term type 1 diabetes. Methods: Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment. The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography. Results: Thirty-seven participants were included in the secondary analysis. No differences in mean peripapillary RNFL thickness (overall ΔMean RNFL thickness; liraglutide -1 (±8) μm (-1%) vs. placebo -1 (±5) μm (-1%), P = 0.78, n = 37) or any of the quadrants. Peripapillary RNFL thicknesses were shown between treatments in either nonproliferative (ΔMean RNFL thickness; liraglutide -1 (±5) μm (-1%) vs. placebo 0 (±4) μm (0%), P = 0.80, N = 26) or proliferative diabetic retinopathy subgroup (ΔMean RNFL thickness; liraglutide -2 (±14) μm (-3%) vs. placebo -1 (±6) μm (-2%), P = 0.88, N = 11). Conclusions: In this study, 26 weeks of liraglutide treatment did not induce measurable changes in the assessed optic nerve thickness. Thus, this methodology does not support the induction of substantial nerve regeneration in this cohort with established retinopathy and DSPN. The trial was approved by the Danish Health and Medicines Authority. Informed consent was obtained from all participants.

AB - Purpose: Liraglutide treatment has shown promising anti-inflammatory and nerve regenerative results in preclinical and clinical trials. We sought to assess if liraglutide treatment would induce nerve regeneration through its anti-inflammatory and neurotrophic mechanisms by increasing peripapillary retinal nerve fiber layer (RNFL) thickness in individuals with long-term type 1 diabetes. Methods: Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment. The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography. Results: Thirty-seven participants were included in the secondary analysis. No differences in mean peripapillary RNFL thickness (overall ΔMean RNFL thickness; liraglutide -1 (±8) μm (-1%) vs. placebo -1 (±5) μm (-1%), P = 0.78, n = 37) or any of the quadrants. Peripapillary RNFL thicknesses were shown between treatments in either nonproliferative (ΔMean RNFL thickness; liraglutide -1 (±5) μm (-1%) vs. placebo 0 (±4) μm (0%), P = 0.80, N = 26) or proliferative diabetic retinopathy subgroup (ΔMean RNFL thickness; liraglutide -2 (±14) μm (-3%) vs. placebo -1 (±6) μm (-2%), P = 0.88, N = 11). Conclusions: In this study, 26 weeks of liraglutide treatment did not induce measurable changes in the assessed optic nerve thickness. Thus, this methodology does not support the induction of substantial nerve regeneration in this cohort with established retinopathy and DSPN. The trial was approved by the Danish Health and Medicines Authority. Informed consent was obtained from all participants.

KW - diabetic retinopathy

KW - GLP-1 agonist

KW - liraglutide

KW - nerve fiber layer

KW - optical coherence tomography

UR - http://www.scopus.com/inward/record.url?scp=85123901088&partnerID=8YFLogxK

U2 - 10.1089/jop.2021.0055

DO - 10.1089/jop.2021.0055

M3 - Journal article

C2 - 34918951

AN - SCOPUS:85123901088

VL - 38

SP - 114

EP - 121

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1

ER -